Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like STew: A new method for unveiling the spatial fingerprint of diseases June 4, 2024 Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes September 17, 2024 Study reveals increased mental health issues among university students during COVID-19 October 30, 2024
Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes September 17, 2024
Study reveals increased mental health issues among university students during COVID-19 October 30, 2024